Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia

2005 ◽  
Vol 29 (6) ◽  
pp. 719-720 ◽  
Author(s):  
Wee J. Chng ◽  
Leonard H.C. Tan
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Late Onset ◽  
Chronic Phase ◽  
Newly Diagnosed

scholarly journals Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

2020 ◽  
Vol 189 (2) ◽  
pp. 303-312 ◽  
Author(s):  
Young Rok Do ◽  
Jae‐Yong Kwak ◽  
Jeong A. Kim ◽  
Hyeoung Joon Kim ◽  
Joo Seop Chung ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Newly Diagnosed ◽  
Phase 3 ◽  
Term Data

scholarly journals Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd

2017 ◽  
Vol 179 (2) ◽  
pp. 219-228 ◽  
Author(s):  
Timothy P. Hughes ◽  
Eduardo Munhoz ◽  
Marco Aurelio Salvino ◽  
Tee Chuan Ong ◽  
Alaa Elhaddad ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Dose Optimization ◽  
Newly Diagnosed

scholarly journals The Management of Chronic Myeloid Leukaemia (CML) Patients with Refractory Disease – Focusing on the Opinions of CML-treating Physicians

2017 ◽  
Vol 13 (01) ◽  
pp. 15
Author(s):  
Ahmet Emre Eskazan ◽  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Myeloid Leukaemia ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Chronic Phase ◽  
Subsequent Paper ◽  
Refractory Disease ◽  
Newly Diagnosed

Although the management of patients with chronic myeloid leukaemia in chronic phase (CML-CP), especially in the newly-diagnosed patient, is generally straightforward, it may vary in the salvage setting, since some of the currently approved tyrosine kinase inhibitors are not available in some countries. This commentary mainly focuses on a questionnaire and the subsequent paper, which were performed in order to understand the perspectives of the CML-treating physicians from different countries in the management of refractory CML-CP.

scholarly journals Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial

2014 ◽  
Vol 168 (1) ◽  
pp. 69-81 ◽  
Author(s):  
Tim H. Brümmendorf ◽  
Jorge E. Cortes ◽  
Cármino Antonio Souza ◽  
Francois Guilhot ◽  
Ladan Duvillié ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document